Related Experiment Video

Updated: Jul 6, 2025

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.0K

Is it time for Heart-Brain clinics? A clinical survey and proposition to improve current care for cognitive problems

Charlotte M Nijskens1,2, Elias G Thomas1,2, Hanneke F M Rhodius-Meester1,3,4,5

  • 1Department of Internal Medicine, Geriatrics Section, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Clinical Cardiology
|January 6, 2024
PubMed

Insights

Cardiologists recognize the importance of screening heart failure patients for cognitive impairment but face barriers like time and expertise. A Heart-Brain care pathway can help implement this crucial screening.

Area of Science:

  • Cardiology
  • Neurology
  • Geriatrics

Background:

  • Cognitive impairment is common in heart failure (HF) patients.
  • Guidelines recommend screening and tailored care for HF patients with cognitive impairment.
  • Practical guidance for HF cognitive impairment screening is lacking.

Purpose of the Study:

  • To explore cardiologists' perspectives on screening and managing cognitive impairment in HF patients.
  • To introduce a multidisciplinary Heart-Brain care pathway for HF cognitive impairment screening.

Main Methods:

  • An online survey was distributed to Dutch cardiologists specializing in Geriatric Cardiology and Heart Failure.
  • The survey assessed current practices, perceived impact of cognitive impairment, and knowledge/skills for recognition.

Main Results:

  • Only 3% of surveyed cardiologists performed structured cognitive screening.
  • 83% felt cognitive impairment is under-addressed; over 50% desired more training.
  • Barriers identified include lack of time and expertise, though 80% agreed screening would benefit patients.

Conclusions:

  • Cardiologists acknowledge the clinical importance of cognitive impairment screening in HF.
  • Lack of time and expertise hinders current screening practices.
  • A Heart-Brain care pathway can facilitate screening and improve personalized care for HF patients.
Abstract

Keywords:
cardiovascular dysfunctioncognitive declineheart failurevascular cognitive impairmentvascular dementia

More Related Videos

Development of a Virtual Reality Assessment of Everyday Living Skills10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.5K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.6K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
388